Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytokine Immune Regulator (CIR) is a preclinical-stage nucleic acid-based immunotherapy being developed by Virothera Pharmaceuticals for the treatment of autoimmune diseases. This DNA/RNA gene therapy is designed to act as an immunomodulator by targeting chemokine receptors specifically associated with T regulatory (Treg) cells. By regulating cytokine signaling and influencing Treg cell activity, the therapy aims to restore immune balance and suppress the aberrant immune responses characteristic of autoimmune conditions. As a nucleic acid-based approach, it represents a novel method of delivering immunomodulatory instructions directly to relevant cell populations to achieve therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cytokine Immune Regulator.